LumaCyte specializes in advanced cellular analytics through its innovative technology, Laser Force Cytology™ (LFC™). This label-free approach allows for the detection of subtle phenotypic changes in cells by measuring optical and fluidic forces without the need for antibody or genetic labeling. The LFC™ technology is integrated into LumaCyte's Radiance® platform, which provides real-time, quantitative analysis of cellular responses. This capability is particularly beneficial for biomanufacturing, enabling developers to monitor critical quality attributes and optimize production processes efficiently. By capturing intrinsic cellular dynamics, LFC™ enhances the understanding of cell behavior in various applications, including cell therapy, gene therapy, and vaccine development.

The Radiance® platform further enhances LumaCyte's offerings by automating the analysis of both adherent and suspension cells in a 96-well plate format. This system is designed to provide rapid insights into cell health, potency, and other critical parameters, facilitating improved production quality and consistency. The platform's Illuminate™ software suite allows for seamless integration into laboratory workflows, maximizing efficiency and ensuring experimental consistency. Overall, LumaCyte's technologies represent a significant advancement in the field of biomanufacturing, providing researchers with the tools necessary for real-time monitoring and optimization of complex biotherapeutic processes.

United States

LumaCyteâs advanced real-time bioanalytics platform, RadianceÂ®, is a label-free, single cell approach for quantitative characterization of innate cellular responses, without the need for antibody or genetic labeling. This revolutionary technology utilizes Laser Force Cytologyâ¢ (LFC) to measure subtle phenotypic changes based purely on the intrinsic biophysical and biochemical properties of cells in response to their environment and/or treatment.

LumaCyte

Company Details